CompletedPHASE2, PHASE3NCT01203358

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Studying Bronchopulmonary dysplasia

Last synced from ClinicalTrials.gov May 21, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: NICHD Neonatal Research Network
Principal Investigator: Jeffrey D. Horbar, MD, MD
University of Vermont
Intervention: Exosurf(drug)
Enrollment: 617 enrolled
Eligibility: All sexes
Timeline: 1991 – 1992

Study locations (13)

Stanford University, Palo Alto, California, United States
Yale University, New Haven, Connecticut, United States
George Washington University, Washington D.C., District of Columbia, United States
University of Miami, Miami, Florida, United States
Emory University, Atlanta, Georgia, United States
Indiana University, Indianapolis, Indiana, United States
Wayne State University, Detroit, Michigan, United States
University of New Mexico, Albuquerque, New Mexico, United States
Cincinnati Children's Medical Center, Cincinnati, Ohio, United States
Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
University of Tennessee, Memphis, Tennessee, United States
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
University of Vermont, Burlington, Vermont, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01203358 on ClinicalTrials.gov

Other trials for Bronchopulmonary dysplasia

Additional recruiting or active studies for the same condition.

See all trials for Bronchopulmonary dysplasia →

← Back to all trials